DGE MRI detects altered glucose uptake and utilization upon microglia activation in Alzheimer’s disease

Research output: Conference PapersRGC 32 - Refereed conference paper (without host publication)peer-review

View graph of relations

Detail(s)

Original languageEnglish
Publication statusPublished - Jun 2023

Meeting

Title2023 ISMRM & ISMRT Annual Meeting & Exhibition
LocationMetro Toronto Convention Centre (MTCC)
PlaceCanada
CityToronto, ON
Period3 - 8 June 2023

Abstract

Introduction
The activation of immune cells is a hallmark of Alzheimer’s disease (AD), especially the microglia . Microglia, one of the most commonly seen cerebral resident cells, facilitated active immune defence in CNS. Based on the cell activation status, microglia could be either pro-inflammatory or anti-inflammatory . Recently, enhanced glucose metabolism and uptake were observed in activated microglia in AD animal model . These distinct glucose alterations may serve as biomarker for early diagnosis in AD. We recently showed the feasibility of using dynamic glucose-enhance (DGE)-MRI in detecting glucose changes in vivo . By injecting natural D-glucose, we would observe the uptake and clearance rate in both brain parenchyma and cerebrospinal fluid (CSF) that could reflect the glucose related events and its metabolism. In this study, we employed DGE-MRI to assess the glucose uptake and utilization in AD, and studied its relationship with immune cells based on our previous study . Microglia and other CNS-invading myeloid cells will be quantified. Activated microglia has a higher expression of CD45 . Proportion and activation of CD11b CD45 microglia and other CNS-invading myeloid cells will be quantified by flow cytometry in APP/PS1 AD model and their littermates. This preliminary result could further support the DGE-MRI findings and related underlying neuropathology.

Methods
All animal experiments were approved by the Animal Ethics Committee and followed the guidelines of Laboratory Animal Research Unit at City University of Hong Kong. APP/PS1 mice (n = 3) and their littermates (n = 3) at 6 months old were used in this study. Mouse was anesthetized by isoflurane during MRI scanning. DGE-MRI was performed as we reported previously at 3 T Bruker BioSpec system (Bruker, Germany) . In general, the signal was measured by the on VDMP sequence. Acquisition parameters are as followings: TR/TE = 2.5 s/4.75 ms, RARE factor = 32, slice thickness = 2 mm, a matrix size of 96 x 96 within a FOV of 18 x 18 mm . CSF and parenchyma images were acquired alternatively (15s per image). Baseline was obtained for 7 minutes followed by 47 minutes acquisition post 50% D-glucose intravenously injection. The kinetic curve was constructed as:  △S(t) = Sbase−S(t) / Sbase.  For the microglia experiment, mouse were sacrificed with CO2 and transcranial perfused with PBS. Subsequently, mouse brains were dissected and minced, and incubated with collagenase for tissue digestion. Cerebral cells were collected after centrifuge. We used cell viability kit for distinguishing dead cells from live cells, Fc blocker to minimize non-specific antibody binding and mouse antibodies to CD45, CD11b for the flow cytometry analysis by flow cytometer (BD FACSVerseTM Cell Analyzer). 

Results
The DGE images of CSF and parenchyma dynamically exhibited the signal change before and after glucose injection, which resembled our previous findings . The preliminary results showed a high parenchymal uptake and a reduced CSF clearance in AD compared to age-matched wild type (WT) (Figure 1). When we compared the cell findings by flow cytometry and DGE with the immune cell findings, we observed a higher CD45l0 CD11b+ microglia cell proportion in APP/PS1 than in WT at 6 months (45.63±1.19% vs 32.73±7.95%, p = 0.049, Figure 2A and B). This increase was also observed in microglia activation (shown as CD45 intensity on CD45l0CD11b+ ), which corresponded to a relatively high parenchymal glucose uptake and low CSF clearance. Meanwhile, other CNS myeloid invading cells (CD45h1 CD11b+ ) did not show differences between groups (Figure 2C).

Discussion
An increase in the glucose uptake in parenchyma was observed, which was also reported by Huang J, et al. 2020 (1.66 ± 0.59% vs 2.16 ± 0.38%) . The DGE findings in this study were comparable with our previous study. Moreover, this corresponds to an increase of microglia proportion and CD45 expression in microglia in AD, which could be attributed to microglial activation . These preliminary results indicated the microglia activation could contribute to the altered glucose uptake and utilization in the brain detected by DGE MRI. We are now investigating the glucose metabolism and its relationship to microglia activation in AD at different stages. We believe the further studies to associate the underlying molecular and cellular pathology of AD with DGE MRI could benefit the identification of AD in early stages.

Conclusion
In the brain, we observed an increase of microglia proportion, as well as activated microglia, accompanied with relatively high parenchymal glucose uptake and low CSF clearance in AD when compared with WT. The preliminary result indicated the abnormal glucose metabolism induced by microglia activation in AD could be detected by DGE-MRI. This potential association of microglia activation and DGE-MRI findings could facilitate the identification of AD.

Citation Format(s)

DGE MRI detects altered glucose uptake and utilization upon microglia activation in Alzheimer’s disease. / Chen, Zilin; Huang, Jianpan; Su, Haoyun et al.
2023. Paper presented at 2023 ISMRM & ISMRT Annual Meeting & Exhibition, Toronto, ON, Canada.

Research output: Conference PapersRGC 32 - Refereed conference paper (without host publication)peer-review